Understanding, Diagnosing, and Using Genetic Testing for Alzheimer Disease 2

Medically reviewed by Brandon Colby, MD, last reviewed Oct 21, 2026

Short answer: Alzheimer disease 2 (AD2) is the OMIM name for late onset Alzheimer disease linked to the APOE ε4 variant. It is a risk association, not a diagnosis: many people with ε4 never develop the disease, and a gene test cannot confirm it. The rare early onset forms caused by PSEN1, PSEN2 or APP variants are different conditions.

Alzheimer Disease 2 (AD2) is a specific subtype of Alzheimer's disease, a neurodegenerative disorder characterized by progressive cognitive decline and memory loss. AD2, like other forms of Alzheimer's, is complex and multifactorial, often involving a combination of genetic, environmental, and lifestyle factors. This article delves into the intricacies of AD2, from understanding its pathology to the role of genetic testing in diagnosis and management.

Understanding Alzheimer Disease 2

Alzheimer disease 2 (AD2) is the OMIM entry (MIM 104310) for Alzheimer disease associated with the APOE ε4 allele. The APOE gene has three common versions, called ε2, ε3 and ε4. Carrying ε4 raises the risk of late onset Alzheimer disease, with two copies raising it more than one, while ε2 is linked to lower risk. The ε4 allele has a worldwide frequency of about 14%. In the brain, Alzheimer disease is marked by amyloid plaques and neurofibrillary tangles that damage nerve cells and lead to cognitive decline.

Diagnosing Alzheimer Disease 2

Diagnosing AD2 involves a combination of clinical assessments, neuroimaging, and laboratory tests. Clinicians look for symptoms such as memory loss, language difficulties, and impaired problem-solving abilities. Neuroimaging techniques, such as MRI and PET scans, help visualize brain atrophy and amyloid deposition. However, these methods alone are not definitive for diagnosing AD2.

The Role of Genetic Testing

For AD2, genetic testing looks at the APOE gene and reports which versions you carry. Variants in PSEN1, PSEN2 and APP cause rare early onset familial Alzheimer disease and are tested separately, usually when symptoms start before age 65 or several relatives are affected. An APOE result shows risk and cannot diagnose Alzheimer disease.

Benefits of Genetic Testing for Alzheimer Disease 2

Genetic testing offers several benefits for individuals at risk of AD2:

Early awareness: an APOE result shows whether your risk is higher or lower than average before symptoms appear, which some people use to start conversations about screening, lifestyle and care planning.
Informed planning: knowing your result can help you and your clinician discuss monitoring, clinical trial options and health habits that support brain health.
Family awareness: an APOE result can prompt relatives to talk with a genetic counselor about their own risk, although one person's result does not predict another's.

Limitations and Ethical Considerations

Genetic testing has limits. Not everyone who carries APOE ε4 develops Alzheimer disease, and people without it can still develop it, so a result cannot predict whether or when symptoms will start. Testing also raises questions about privacy, insurance and emotional impact. Genetic counseling before and after testing helps people understand what a result means.

Conclusion

Alzheimer disease 2 describes the link between the APOE ε4 variant and late onset Alzheimer disease. An APOE result shows risk, not a diagnosis, and the early onset forms caused by PSEN1, PSEN2 and APP variants are tested separately. Genetic counseling helps put any result in context.

Get Tested With Whole Genome Sequencing

Whole genome sequencing reads 100% of your DNA, including over 30,000 genes, and your data includes your APOE genotype. Every Sequencing Kit Bundle includes Next Gen Disease Screening, which analyzes your genome for more than 15,000 conditions, and the Comprehensive and Professional bundles include a Brain Health report. A genetic result shows risk, not a diagnosis, so talk with a clinician or genetic counselor before acting on it.

Shop All Whole Genome Sequencing Kit Bundles

Frequently Asked Questions

What is Alzheimer disease 2?

Alzheimer disease 2 (AD2) is the name OMIM uses for late onset Alzheimer disease associated with the APOE ε4 variant. It describes a risk association and is not a separate disease that a gene test can diagnose.

Is AD2 the same as early onset Alzheimer disease?

No. Early onset familial Alzheimer disease is rare, starts before age 65 and is caused by variants in the APP, PSEN1 or PSEN2 genes. AD2 refers to the APOE ε4 association with the more common late onset form.

Does carrying APOE ε4 mean I will get Alzheimer disease?

No. APOE ε4 raises risk, and two copies raise it more than one, but many carriers never develop Alzheimer disease and some people without it do. A result cannot predict whether or when symptoms will start.

Should I get tested for APOE?

APOE testing is a personal choice and is not routinely recommended to predict risk in people without symptoms. If you are considering it, speak with a clinician or genetic counselor first so you understand what the result can and cannot tell you.

Sources and Patient Organizations

This page is for education and is not medical advice. Genetic results show risk and do not diagnose a condition. Talk with a clinician or genetic counselor about your results.